Recently, targeted therapy that is based on the mutation state of molecular biomarkers has been developed for the treatment of non–small‐cell lung cancer.60 In fact, approximately 60%‐80% of the patients whose tumor samples contain somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene respond to EGFR tyrosine kinase inhibitors (TKIs).61 Mutated KRAS, v‐erb‐b2 erythroblastic leukemia viral oncogene homolog 2 (HER‐2), and serine‐threonine kinase BRAF are also involved in the development and progression of NSCLC.62, 63. Here, KRAS is linked to non-small cell lung carcinoma.